Work

Interim safety results of eribulin (E) combined with ramucirumab (RAM) in patients (pts) with advanced metastatic breast cancer (MBC).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.27_suppl.110

Authors: Denise Aysel Yardley, Cynthia R. C. Osborne, Paul D. Richards, Brooke R. Daniel, Michael A. Danso, Anne Favret, Jane Bromund, Yanzhi Hsu, Ayman B. Ibrahim

Institutions: Sarah Cannon, Tennessee Oncology, Texas Oncology, Virginia Oncology Associates, Virginia Cancer Specialists, Eli Lilly (United States)

Language: English

Topic: Cancer Treatment and Pharmacology

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2586862487

Cites:

Cited by: 2

Related to: 10